Biomarkers for the early detection of breast cancer

A method comprising;

• (a) contacting a serum or plasma sample obtained from a subject having or at risk of having breast cancer with a polypeptide probe set bound to a surface of a solid support, wherein the polypeptide probe set comprises CTBP1 polypeptide (SEQ ID NO:
• 29) or an antigenic fragment thereof, BDNF (SEQ ID NO:
• 17) or an antigenic fragment thereof, GPR157 (SEQ ID NO:
• 43) or an antigenic fragment thereof, and one or more additional polypeptides selected from the group consisting of ATP6AP1 (SEQ ID NO:
• 13), PDCD6IP (SEQ ID NO:
• 21), DBT (SEQ ID NO:
• 25), CSNK1E (SEQ ID NO:
• 9), FRS3 (SEQ ID NO:
• 3), RAC3 (SEQ ID NO:
• 15), HOXD1 (SEQ ID NO:
• 7), SF3A1 (SEQ ID NO:
• 1), C15orf48 (SEQ ID NO:
• 35), MYOZ2 (SEQ ID NO:
• 33), EIF3E (SEQ ID NO:
• 39), BAT4 (SEQ ID NO:
• 5), ATF3 (SEQ ID NO:
• 19), BMX (SEQ ID NO:
• 45), RAB5A (SEQ ID NO:
• 23), UBAP1 (SEQ ID NO:
• 47), SOX2 (SEQ ID NO:
• 31), ZMYM6 (SEQ ID NO:
• 41), SLC33A1 (SEQ ID NO:
• 11), TRIM32 (SEQ ID NO:
• 37), ALG10 (SEQ ID NO:
• 27), TFCP2 (SEQ ID NO:
• 49), SERPINH1 (SEQ ID NO:
• 51), SELL (SEQ ID NO:
• 55), ZNF510 (SEQ ID NO:
• 53), and antigenic fragments thereof;
• wherein the contacting occurs under conditions whereby antibodies, if present in the bodily fluid, selectively bind to the polypeptides bound to the surface;
• (b) detecting presence of antibodies to the polypeptides in the sample;
• wherein the presence of antibodies in the sample to the one or more polypeptides is used to diagnose breast cancer in the subject, and wherein detecting comprises normalizing intensities for each polypeptide of the probe set and comparing normalized intensities with a control using partial area under a receiver operating characteristic curve (pAUC) with a false positive rate no greater than 5 percent;
• and
• (c) administering a therapeutic agent to the subject to treat the breast cancer.